Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/Ib study of RO7198457 alone and with atezolizumab in advanced or metastatic solid tumors
NL-OMON55424Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of autogene cevumeran and atezolizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and 10 more (2 arms), sponsored by Roche. Primary endpoints: Incidence and nature of dose-limiting toxicities, Adverse events and 4 more. Started Feb 2019; status: completed.
02
Drugs
autogene cevumeranatezolizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON55424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55424.